Hong Kong-based China Grand Pharmaceutical and Healthcare Holdings has invested $27 million in the Hamden-based company CoRISMA MCS Systems.
The early-stage medical device startup will use the funds to take the heart failure device through development and preclinical trials. Grand Pharma will hold a 22% equity interest in the company and will gain distribution rights to the Greater China market.